INVO Bioscience Q3 revenue ex-license $235K, up 484% YoY; cash $0.3M, closes $0.35M debt

INVO Fertility, Inc.

2022-Q3 EPS reported -$0.67 revenue$544,054

Revenue (ex-license) $235,321 (+484% YoY, +61% sequential); clinic revenue $176,395 (+370%), product sales $58,926 (+2,012%).
Combined clinic revenue (consolidated + equity) $450,131 (+1,100% YoY, +111% sequential).
Cash $0.3M at Sept 30; raised $0.35M in interim demand notes post-quarter; seeking additional funding.
Adjusted EBITDA -$2.0M vs -$1.6M; gross margin 54% vs 49% adjusted prior year; no GAAP net income disclosed.
Completed due diligence on clinic acquisition; Tampa INVO Center expected Q1 2023; updated 510(k) filed for 5-day incubation.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INVO Fertility, Inc. reported the third quarter ended September 30, 2022 results: revenue $235,321.

Period: the third quarter ended September 30, 2022
Revenue: $235,321
Result: reported results

Exact text from the filing

Revenue for the three months ended September 30, 2022, was $235,321 compared to $218,874 for the three months ended September 30, 2021.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-032043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.